Axsome Therapeutics Stock Rises Over 20% in April Due to FDA Approval for New Indication
Axsome Therapeutics (AXSM) stock surged over 20% in April 2026 following the FDA's approval of its drug Auvelity for treating agitation associated with Alzheimer's disease. This new indication is expected to open a potential $2 billion market opportunity. The company's sales of Auvelity, which treats major depressive disorder, grew 74% in 2025.
Tickers: $AXSM
Topics: Alzheimer's disease drug sales FDA approval pharmaceuticals stock performance